GoodRx Holdings (GDRX) Net Income towards Common Stockholders (2019 - 2026)

GoodRx Holdings has reported Net Income towards Common Stockholders for 8 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 89.42% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (down 27.75% YoY) and the FY2025 annual result came in at $30.4 million, up 85.72% from the prior year.
• Net Income towards Common Stockholders fell to $1.2 million in Q1 2026 per GDRX's latest filing, from $5.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $58.8 million in Q2 2023 and troughed at -$41.7 million in Q3 2022.
• A 5-year average of $370705.9 and a median of $1.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 4254.49% in 2023, down 1211.82% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$2.0 million in 2022, then slumped by 1211.82% to -$25.9 million in 2023, then surged by 126.05% to $6.7 million in 2024, then retreated by 19.51% to $5.4 million in 2025, then tumbled by 78.45% to $1.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $1.2 million, $5.4 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.